Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02403440
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Recruiting
Phase Phase 1
Start date April 2014

See also
  Status Clinical Trial Phase
Completed NCT01356511 - High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Phase 4
Completed NCT00540423 - Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00372892 - Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) Phase 2
Not yet recruiting NCT03252457 - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Phase 3
Completed NCT00151840 - Efficacy and Safety of IVIG-L in ITP Patients Phase 3
Recruiting NCT05438875 - The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 Phase 3
Completed NCT02281370 - Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects Phase 1
Terminated NCT00547066 - Study of Veltuzumab (hA20) at Different Doses in Patients With ITP Phase 1/Phase 2
Completed NCT00370331 - RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag Phase 3
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00487968 - Eltrombopag Taste Testing in Healthy Adult Volunteers Phase 1
Withdrawn NCT01317966 - Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia N/A
Not yet recruiting NCT03443570 - Rituximab Combining Bortezomib Versus Rituximab in Management of ITP Phase 3
Completed NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Phase 2
Completed NCT02201290 - A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00220727 - Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP Phase 2
Completed NCT02334813 - Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Phase 3
Completed NCT02891109 - Regulatory B Cells and Chronic Immune Thrombocytopenia N/A
Completed NCT00706342 - Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT03258866 - The Study of Different Dose Rituximab in the Treatment of ITP Phase 4